C
Climb Bio, Inc. (CLYM)
NGM – Real Time Price. Currency in USD
11.17
+0.05 (0.45%)
At close: May 12, 2026, 4:00 PM EDT
11.12
-0.05 (-0.45%)
After-hours: May 12, 2026, 6:31 PM EDT
Get all premium features to the best stock analysis tool
Find any stock by ticker or company name
NGM – Real Time Price. Currency in USD
11.17
+0.05 (0.45%)
At close: May 12, 2026, 4:00 PM EDT
11.12
-0.05 (-0.45%)
After-hours: May 12, 2026, 6:31 PM EDT
Revenue breakdown data has not been calculated yet.
No Data
There are no news for this stock.
| NAME | RATIO | INDUSTRY | 5Y TREND | SCORE |
|---|---|---|---|---|
| Current ratio | 27.86 | 6.05 | 10 | |
| Quick ratio | 27.86 | 5.63 | 10 | |
| Debt to Equity | 0.00 | 0.30 | 10 | |
| Debt to Assets | 0.00 | 1.04 | 10 | |
| Interest coverage | N/A | -16.91 | 1.0 | |
| Weighted average score | 8.2 | |||
| METRIC | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|
| Total Revenue | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | N/A | N/A | N/A | -97K | -135K |
| Operating Income | -45M | -40M | -27M | -68M | -60M |
| Net Income | -45M | -35M | -74M | -60M | -53M |
| EBITDA | -45M | -40M | -27M | -68M | -60M |
| NAME | RATIO | INDUSTRY | 5Y TREND | SCORE |
|---|---|---|---|---|
| Gross margin % | N/A | -11.73 | 1.0 | |
| Operating margin % | N/A | -24.60 | 1.0 | |
| Net margin % | N/A | -172.20 | 1.0 | |
| EBITDA margin % | N/A | -201.27 | 1.0 | |
| Cash flow margin % | N/A | -156.39 | 1.0 | |
| Weighted average score | 1.0 | |||
| NAME | REVENUE GROWTH | EPS GROWTH | SCORE |
|---|---|---|---|
| Current quarter | N/A | -81.66 | 1.0 |
| Next quarter | N/A | -26.1 | 1.0 |
| Current year | N/A | -12.16 | 1.0 |
| Next year | N/A | -22.15 | 1.0 |
| Weighted average score | 1.0 | ||
| NAME | REVENUE | NET INCOME | EPS | FCF | SCORE |
|---|---|---|---|---|---|
| Q/Q | 999 | 21.66 | 23.08 | 8.03 | 9.0 |
| Y/Y | 999 | 33.97 | 35.48 | 6.84 | 8.8 |
| 3y average | 999 | -23 | N/A | -60.37 | 3.3 |
| 5y average | 999 | -38.8 | N/A | -68.11 | 3.3 |
| Weighted average score | 6.1 | ||||
| NAME | CURRENT | INDUSTRY | SCORE |
|---|---|---|---|
| Dividend yield | 0.00 | N/A | 1.0 |
| Payout ratio | 0.00 | N/A | 1.0 |
| 5-year dividend growth rate | N/A | N/A | 1.0 |
| Years of dividend increase | N/A | N/A | 1.0 |
| Weighted average score | 1.0 | ||
| NAME | SCALE | SCORE |
|---|---|---|
| Market share | None | 1.0 |
| Intangible assets | None | 1.0 |
| Switching costs | None | 1.0 |
| Network effect | None | 1.0 |
| Economies of scale | None | 1.0 |
| Weighted average score | 1.0 | |
Company's cash reserves $8.4M significantly exceed its total debt $479.0K, ensuring strong financial flexibility
Total current assets $113.4M exceed Total current liabilities $4.1M, highlighting excellent liquidity
Debt-to-equity ratio (0.0) is well below the industry average (0.3), showcasing prudent financial management
Interest expense exists but EBIT data is unavailable, indicating potential profitability concerns
Negative free cash flow -$14.4M limits the company's ability to reinvest or pay down debt